Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Mohan · SciRah

Researcher profile · Semantic Scholar

M. Mohan

Share profile

M. Mohan — researcher profile on SciRah

h-index: 23
Works: 175
Citations: 1,563

Most-cited papers

Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
M. Mohan, Jorge Monge, Nishi Shah, Danny Luan +17 more
2024Blood Cancer Journal84 citations Open access
Semantic Scholar
Recommendations on Prevention of Infections during Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma
M. Mohan, R. Chakraborty, S. Bal, A. Nellore +6 more
2023British Journal of Haematology83 citations Open access
Semantic Scholar
The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
Lindsay Hammons, A. Szabo, A. Janardan, Vineel Bhatlapenumarthi +16 more
2023Haematologica58 citations Open access
Semantic Scholar
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
Jing Dong, Z. Garacci, Christopher Staffi Buradagunta, A. D'Souza +6 more
2022Blood Cancer Journal50 citations Open access
Semantic Scholar
Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma.
William Wesson, D. Dima, Nahid Suleman, M. Saif +17 more
2024Transplantation and Cellular Therapy43 citations Open access
Semantic Scholar
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
M. Mohan, A. Szabo, Heloise Cheruvalath, Anna Clennon +19 more
2025Blood Cancer Journal37 citations Open access
Semantic Scholar
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, M. Mohan +2 more
2023Blood Cancer Journal32 citations Open access
Semantic Scholar
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels
R. Banerjee, M. Mohan, K. Rejeski, Benjamin R. Puliafito +8 more
2025Blood Advances31 citations
Semantic Scholar
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma
M. Mohan, A. Szabo, Anannya Patwari, Jean Esselmann +18 more
2024Bone Marrow Transplantation26 citations
Semantic Scholar
Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention
F. Furqan, Vineel Bhatlapenumarthi, B. Dhakal, T. Fenske +11 more
2024Blood Advances26 citations Open access
Semantic Scholar
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, A. Szabo +13 more
2024Blood Cancer Journal24 citations Open access
Semantic Scholar
Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
M. Mohan, Nishi Shah, Danny Luan, Jorge Monge +17 more
2023Blood24 citations Open access
Semantic Scholar
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
Samer al Hadidi, A. Szabo, Jean Esselmann, Lindsay Hammons +16 more
2022Bone Marrow Transplantation24 citations
Semantic Scholar
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
M. Mohan, Oliver Van Oekelen, O. Akhtar, Adam D. Cohen +1 more
2024American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting22 citations
Semantic Scholar
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
B. Dhakal, R. Silbermann, T. Schmidt, E. Medvedova +26 more
2024Blood22 citations
Semantic Scholar
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Samer al Hadidi, A. Szabo, Bhavesh Mohan Lal, Aishee Bag +14 more
2025Blood Cancer Journal19 citations Open access
Semantic Scholar
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
Zimu Gong, G. Umoru, Jorge Monge, Nishi Shah +7 more
2024Blood Cancer Journal19 citations Open access
Semantic Scholar
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review
Karun Neupane, G. Fortuna, Riyasha Dahal, T. Schmidt +8 more
2024Blood Cancer Journal18 citations Open access
Semantic Scholar
Clinical efficacy of retreatment of daratumumab‐based therapy (D2) in daratumumab‐refractory multiple myeloma
Al-Ola A. Abdallah, Z. Mahmoudjafari, N. Ahmed, Wei Cui +7 more
2023European Journal of Haematology13 citations
Semantic Scholar
Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients
Farheen Chunara, Chris Lugo, Kristen Osinski, Mansi R. Shah +12 more
2025Blood Cancer Journal12 citations Open access
Semantic Scholar
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study
Heloise Cheruvalath, Anna Clennon, Asis Shrestha, A. Szabo +19 more
2024Blood10 citations
Semantic Scholar
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
M. Mohan, Z. Gong, T. Ashby, Samer al Hadidi +9 more
2023Cancer10 citations
Semantic Scholar
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation
S. Chhabra, James H. Jerkins, K. Monahan, A. Szabo +13 more
2024Bone Marrow Transplantation9 citations
Semantic Scholar
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Kristin T Larsen, H. Spencer, M. Mohan, Clyde Bailey +21 more
2022Journal of Clinical Medicine9 citations Open access
Semantic Scholar
Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort
Alexandra Noveihed, Samer al Hadidi, M. Mohan, Mansi R. Shah
2025British Journal of Haematology8 citations Open access
Semantic Scholar
Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation
Lindsay R Hammons, Shabi Haider, A. Portuguese, R. Banerjee +13 more
2023British Journal of Haematology8 citations
Semantic Scholar
Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.
Agrima Mian, S. Naqvi, A. Ayaz, Muhammad Husnain +6 more
2023Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis6 citations
Semantic Scholar
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma
M. Mohan, Sravani Gundarlapalli, A. Szabo, N. Yarlagadda +15 more
2022American journal of hematology/oncology6 citations
Semantic Scholar
Neutralizing antibody responses against SARS‐CoV‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
Al-Ola A. Abdallah, Z. Mahmoudjafari, Tahani Atieh, N. Ahmed +9 more
2022European Journal of Haematology6 citations Open access
Semantic Scholar
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Doris K. Hansen, Danai Dima, H. Mian, Jakob Devos +26 more
2026Blood Cancer Journal5 citations
Semantic Scholar
Current Status on Management of Primary Plasma Cell Leukemia
Zimu Gong, Meera Khosla, Sreeraj Vasudevan, M. Mohan
2024Current Oncology Reports5 citations
Semantic Scholar
Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort
Metodi Balev, Nishi Shah, Mansi R. Shah, Anannya Patwari +19 more
2024Blood5 citations
Semantic Scholar
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience
M. Mohan, M. Becnel, U. Shah, Hua-jiang Dong +28 more
2022American journal of hematology/oncology5 citations Open access
Semantic Scholar
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia
Asis Shrestha, S. Thanendrarajan, Aishee Bag, B. Dhakal +8 more
2025Blood Advances4 citations
Semantic Scholar
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma
Stephanie Yohay, Temitope Oloyede, Soyoung Kim, Xi Fang +9 more
2024British Journal of Haematology4 citations Open access
Semantic Scholar
Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma
Amrita Y. Krishnan, Krina K. Patel, M. Mohan, Sundar Jagannath +7 more
2024Blood neoplasia4 citations Open access
Semantic Scholar
Adverse Effects and Non-Relapse Mortality of BCMA-Directed Immunotherapies : An FDA Adverse Event Reporting System (FAERS) Database Study
Zimu Gong, G. Umoru, Jorge Monge, Nishi Shah +6 more
2023Blood4 citations Open access
Semantic Scholar
Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis
H. Mian, M. Faisal, Tie-Ning Chen, R. Brazauskas +28 more
2025Blood3 citations
Semantic Scholar
Application of Stem Cell Boost for Immune Effector Cell Associated Hematotoxicity (ICAHT) Following BCMA Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma (MM)
Kritika Yadav, T. Patel, Ramya Bachu, Jean Esselmann +17 more
2024Blood3 citations
Semantic Scholar
Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention
F. Furqan, Vineel Bhatlapenumarthi, Faiqa Farrukh, T. Fenske +10 more
2024Transplantation and Cellular Therapy3 citations Open access
Semantic Scholar
A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
Ariel A. Kleman, Arun K Singavi, L. Pommert, Angela J. Mathison +11 more
2023Blood Advances3 citations Open access
Semantic Scholar
Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma
F. Schjesvold, Andrew Spencer, Y. Cohen, E. Ocio +15 more
2023Blood3 citations Open access
Semantic Scholar
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).
A. Janardan, H. Lindsay, A. Szabo, Vineel Bhatlapenumarthi +15 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability
M. Mohan, N. Danziger, O. Akhtar, Ravi K. Narra +7 more
2025Blood Advances2 citations Open access
Semantic Scholar
Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma
Gala Vega, Daniel Morillo, C. Riedhammer, Aishee Bag +18 more
2025Blood2 citations
Semantic Scholar
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies
O. Akhtar, A. Szabo, Vineel Bhatlapenumarthi, Mark Forsberg +20 more
2024British Journal of Haematology2 citations
Semantic Scholar
Risk stratification in multiple myeloma: Are we there yet?
M. Mohan, C. Schinke
2024British Journal of Haematology2 citations Open access
Semantic Scholar
PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis
Tarang Sharma, Maday Galeana Figueroa, K. Nyati, M. Mohan +2 more
2024Blood2 citations
Semantic Scholar
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study
M. Mohan, A. Kothari, Nathaniel Verhagen, A. Shreenivas +10 more
2023Bone Marrow Transplantation2 citations
Semantic Scholar
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma.
Hamza Hashmi, Atrash Shebli, Jayanshu Jain, Ghena Khasawneh +7 more
2023Transplantation and Cellular Therapy2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Schinke×24
Invite
C. Schinke — researcher profile on SciRah
B. Dhakal×22
Invite
B. Dhakal — researcher profile on SciRah
Samer al Hadidi×18
Invite
Samer al Hadidi — researcher profile on SciRah
S. Thanendrarajan×15
Invite
S. Thanendrarajan — researcher profile on SciRah

×15

Invite

M. Zangari — researcher profile on SciRah

Anita D'Souza×13

Invite

Anita D'Souza — researcher profile on SciRah

Invite

A. Szabo — researcher profile on SciRah

Vineel Bhatlapenumarthi×11

Invite

Vineel Bhatlapenumarthi — researcher profile on SciRah

Divaya Bhutani×10

Invite

Divaya Bhutani — researcher profile on SciRah

F. van Rhee×10

Invite

F. van Rhee — researcher profile on SciRah

Invite

O. Akhtar — researcher profile on SciRah

Rajshekhar Chakraborty×9

Invite

Rajshekhar Chakraborty — researcher profile on SciRah